Drug Profile
Fimaporfin delivered cancer vaccine - PCI Biotech
Alternative Names: fimaVACCLatest Information Update: 26 May 2023
Price :
$50
*
At a glance
- Originator PCI Biotech
- Class Antineoplastics; Benzenesulfonates; Cancer vaccines; Porphyrins; Small molecules
- Mechanism of Action Photosensitisers; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 15 May 2023 PCI Biotech files for patent protection for undisclosed treatment in USA
- 18 Aug 2022 PCI Biotech terminates a phase II trial in Head and neck cancer because previously reported efforts to finance the planned trial were not under the current market conditions that resulted in a feasible way forward (Intradermal)
- 11 May 2022 Preclinical development is ongoing in United Kingdom